MilliporeSigma
  • Home
  • Search Results
  • Inhibition of airway inflammation by the roots of Angelica decursiva and its constituent, columbianadin.

Inhibition of airway inflammation by the roots of Angelica decursiva and its constituent, columbianadin.

Journal of ethnopharmacology (2014-07-30)
Hun Jai Lim, Ju Hee Lee, Jae Sue Choi, Sang Kook Lee, Yeong Shik Kim, Hyun Pyo Kim
ABSTRACT

The roots of Angelica decursiva Fr. Et Sav (Umbelliferae) have been frequently used in traditional medicine as anti-inflammatory, antitussive, analgesic agents and expectorant, especially for treating cough, asthma, bronchitis and upper respiratory tract infections. To establish the scientific rationale for the clinical use of Angelica decursiva and to identify new agents for treating inflammatory lung disorders, pharmacological evaluation of the roots of Angelica decursiva and the isolated constituents was performed. In vitro study was carried out using two lung cells, lung epithelial cells (A549) and alveolar macrophages (MH-S). The inflammatory markers such as IL-6 and nitric oxide (NO) for each cell line were examined. For in vivo study, a mouse model of lipopolysaccharide (LPS)-induced acute lung injury was used and the effects on lung inflammation were established by measuring the cell numbers in bronchoalveolar lavage fluid (BALF) and by histological observation. Water and 70% ethanol extracts of the roots of Angelica decursiva showed considerable inhibitory activity against LPS-induced lung inflammation in mice following oral administration at a dose of 400 mg/kg. Five coumarin derivatives including columbianadin, umbelliferone, umbelliferone 6-carboxylic acid, nodakenin and nodakenetin were isolated. Among the isolated compounds, columbianadin was found to possess strong inhibitory activity against the inflammatory response of IL-1β-treated A549 cells and LPS-treated MH-S cells. Columbianadin was found to inhibit NO production by down-regulation of inducible NO synthase. Moreover, columbianadin was also proved to possess significant inhibitory activity against LPS-induced lung inflammation following oral administration at a dose of 20-60 mg/kg. The roots of Angelica decursiva were proved to be effective in the treatment of lung inflammation. Columbianadin can be a potential new agent for treating inflammatory lung disorders.

MATERIALS
Product Number
Brand
Product Description

Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Rat Interleukin-6 ELISA Kit, for for cell lysate and tissue lysate
Sigma-Aldrich
Mouse IL-6 R ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Human IL-6 ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Human IL-6 ELISA Kit, for cell and tissue lysates
Sigma-Aldrich
Rat IL-6 ELISA Kit, for serum, plasma and cell culture supernatants
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Mouse IL-6 ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Human IL-6 sR ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Mouse IL-6 ELISA Kit, for cell and tissue lysates
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard